source
- Roche reaffirms sales outlook despite weaker Xolair sales and looming generic competitionRoche reported third-quarter group sales of 16.1 billion Swiss francs, about $19.6 billion, a 7% increase that beat analysts' consensus estimate of 15.8 billion francs. The beat was helped by a ne…
- Biotech sector logs 31 IPOs in 2026, with four more slated, still far below 2021 boomBiotech IPO activity has accelerated this year, with 31 companies completing public offerings so far, according to BioSpace data. This figure exceeds the totals from each of the previous four year…